|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
NZ537277A
(en)
|
2002-07-18 |
2008-04-30 |
Crucell Holland Bv |
Recombinant production of mixtures of antibodies
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
WO2004106375A1
(en)
|
2003-05-30 |
2004-12-09 |
Merus Biopharmaceuticals B.V. I.O. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
|
EP2064325B1
(en)
|
2006-09-01 |
2011-12-07 |
Therapeutic Human Polyclonals, Inc. |
Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
|
|
EP3456191A1
(en)
*
|
2008-06-27 |
2019-03-20 |
Merus N.V. |
Antibody producing non-human mammals
|
|
KR101711222B1
(ko)
|
2008-12-18 |
2017-02-28 |
에라스무스 유니버시티 메디컬 센터 로테르담 |
인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
DK3241435T3
(da)
|
2009-07-08 |
2021-08-23 |
Kymab Ltd |
Dyremodeller og terapeutiske molekyler
|
|
US20120021409A1
(en)
*
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US20130185821A1
(en)
*
|
2010-02-08 |
2013-07-18 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
SG183149A1
(en)
|
2010-02-08 |
2012-09-27 |
Regeneron Pharma |
Common light chain mouse
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
MY195217A
(en)
*
|
2010-06-22 |
2023-01-11 |
Regeneron Pharma |
MICE Expressing An Immunoglobulin Hybrid Light Chain
|
|
EP2601298B1
(en)
|
2010-08-02 |
2016-11-30 |
Regeneron Pharmaceuticals, Inc. |
Mice that make binding proteins comprising vl domains
|
|
CN105950654B
(zh)
*
|
2010-11-27 |
2020-03-20 |
朱坚 |
一种人源化的转基因动物
|
|
CN105861548B
(zh)
|
2011-02-25 |
2020-01-10 |
瑞泽恩制药公司 |
Adam6小鼠
|
|
JP5768147B2
(ja)
|
2011-02-28 |
2015-08-26 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
一価抗原結合タンパク質
|
|
WO2012116926A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Antigen binding proteins
|
|
ES2872081T3
(es)
|
2011-08-05 |
2021-11-02 |
Regeneron Pharma |
Ratones con cadena ligera universal humanizada
|
|
WO2013041845A2
(en)
*
|
2011-09-19 |
2013-03-28 |
Kymab Limited |
Animals, repertoires & methods
|
|
AU2012311286B2
(en)
|
2011-09-19 |
2018-07-26 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
GB2495083A
(en)
*
|
2011-09-26 |
2013-04-03 |
Kymab Ltd |
Human VpreB and chimaeric surrogate light chains in transgenic non-human vertebrates
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
DK2760471T3
(en)
*
|
2011-09-30 |
2017-05-08 |
Dana Farber Cancer Inst Inc |
THERAPEUTIC PEPTIDES
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
EP4074833A1
(en)
|
2011-10-17 |
2022-10-19 |
Regeneron Pharmaceuticals, Inc. |
Restricted immunoglobulin heavy chain mice
|
|
WO2013063391A2
(en)
|
2011-10-28 |
2013-05-02 |
Trianni, Inc. |
Transgenic animals and methods of use
|
|
US9253965B2
(en)
*
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
SMT201900296T1
(it)
|
2011-12-20 |
2019-07-11 |
Regeneron Pharma |
Topi di catena leggera umanizzata
|
|
MX2014010527A
(es)
|
2012-03-02 |
2014-10-14 |
Regeneron Pharma |
Anticuerpos humanos para toxinas de clostridium difficile.
|
|
JP2015509380A
(ja)
*
|
2012-03-06 |
2015-03-30 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
共通の軽鎖のマウス
|
|
US9801362B2
(en)
*
|
2012-03-16 |
2017-10-31 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing pH-sensitive immunoglobulin sequences
|
|
AU2015227453B2
(en)
*
|
2012-03-16 |
2017-05-25 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
|
WO2013138681A1
(en)
*
|
2012-03-16 |
2013-09-19 |
Regeneron Pharmaceuticals, Inc. |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
|
HUE037659T2
(hu)
|
2012-03-16 |
2018-09-28 |
Regeneron Pharma |
Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
WO2013157953A1
(en)
|
2012-04-20 |
2013-10-24 |
Merus B.V. |
Methods and means for the production of ig-like molecules
|
|
EP3553089A1
(en)
*
|
2012-05-10 |
2019-10-16 |
Bioatla, LLC |
Multi-specific monoclonal antibodies
|
|
SG10201609535TA
(en)
*
|
2012-06-05 |
2017-01-27 |
Regeneron Pharma |
Methods for making fully human bispecific antibodies using a common light chain
|
|
NZ703689A
(en)
|
2012-06-12 |
2016-05-27 |
Regeneron Pharma |
Humanized non-human animals with restricted immunoglobulin heavy chain loci
|
|
US20150203591A1
(en)
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
|
JO3462B1
(ar)
|
2012-08-22 |
2020-07-05 |
Regeneron Pharma |
أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
BR112015006824A2
(pt)
|
2012-09-27 |
2017-07-04 |
Merus B V |
anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
|
|
KR102391731B1
(ko)
|
2013-01-14 |
2022-04-27 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
US9848587B2
(en)
|
2013-02-20 |
2017-12-26 |
Regeneron Pharmaceuticals, Inc. |
Humanized T cell co-receptor mice
|
|
RS57582B1
(sr)
|
2013-02-20 |
2018-11-30 |
Regeneron Pharma |
Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
|
|
SI2958937T1
(sl)
*
|
2013-02-22 |
2018-12-31 |
Regeneron Pharmaceuticals, Inc. |
Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks
|
|
AU2014249148B2
(en)
*
|
2013-03-11 |
2020-04-02 |
Regeneron Pharmaceuticals, Inc. |
Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
|
|
HUE061977T2
(hu)
*
|
2013-03-13 |
2023-09-28 |
Regeneron Pharma |
Korlátozott immumglobulin könnyûlánc-repertoárt expresszáló egerek
|
|
KR20150126863A
(ko)
*
|
2013-03-13 |
2015-11-13 |
리제너론 파마슈티칼스 인코포레이티드 |
공통 경쇄 마우스
|
|
PL2967012T3
(pl)
|
2013-03-14 |
2021-04-19 |
Erasmus University Medical Center Rotterdam |
Transgeniczne ssaki inne niż człowiek do wytwarzania przeciwciał
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
KR102049990B1
(ko)
|
2013-03-28 |
2019-12-03 |
삼성전자주식회사 |
c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
|
|
CA2904806C
(en)
|
2013-04-29 |
2021-11-23 |
F. Hoffmann-La Roche Ag |
Human fcrn-binding modified antibodies and methods of use
|
|
US20150033372A1
(en)
*
|
2013-05-01 |
2015-01-29 |
Kymab Limited |
Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
MY191512A
(en)
|
2013-09-18 |
2022-06-28 |
Regeneron Pharma |
Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
|
|
MX2016003617A
(es)
|
2013-09-30 |
2016-07-21 |
Chugai Pharmaceutical Co Ltd |
Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
|
|
WO2015049517A2
(en)
*
|
2013-10-01 |
2015-04-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
BR112016006929A2
(pt)
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
|
|
CN110903398B
(zh)
|
2014-01-15 |
2023-08-15 |
豪夫迈·罗氏有限公司 |
具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
|
|
CN110981957B
(zh)
|
2014-01-15 |
2024-12-24 |
豪夫迈·罗氏有限公司 |
具有改善的蛋白A结合作用的Fc区变体
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
CA2941030C
(en)
|
2014-02-28 |
2025-05-13 |
Merus N.V. |
ANTIBODIES THAT BIND TO EGFR AND ERBB3
|
|
DK3805268T3
(da)
|
2014-02-28 |
2025-01-20 |
Merus Nv |
Antistof, der binder erbb-2 og erbb-3
|
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
AU2015230938C1
(en)
*
|
2014-03-21 |
2021-10-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
|
SG10201808083VA
(en)
|
2014-03-21 |
2018-10-30 |
Regeneron Pharma |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
CR20160519A
(es)
|
2014-05-13 |
2017-01-27 |
The Trustees Of The Univ Of Pennysylvania |
Composiciones que comprenden avv que expresa constructos de anticuerpos duales y sus usos
|
|
PL3151921T3
(pl)
|
2014-06-06 |
2020-02-28 |
Bristol-Myers Squibb Company |
Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
|
|
US20160081314A1
(en)
|
2014-09-19 |
2016-03-24 |
Regeneron Pharmaceuticals, Inc. |
Chimeric Antigen Receptors
|
|
WO2016054598A2
(en)
|
2014-10-03 |
2016-04-07 |
Massachusetts Institute Of Technology |
Antibodies that bind ebola glycoprotein and uses thereof
|
|
RU2713131C1
(ru)
|
2014-11-06 |
2020-02-03 |
Ф. Хоффманн-Ля Рош Аг |
ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМИ СВОЙСТВАМИ СВЯЗЫВАНИЯ FcRn И БЕЛКА А
|
|
ES2809455T3
(es)
|
2014-11-17 |
2021-03-04 |
Regeneron Pharma |
Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
|
|
JP6805142B2
(ja)
|
2014-11-21 |
2020-12-23 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｃｄ７３に対する抗体およびその使用
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
HK1245171A1
(zh)
|
2014-11-26 |
2018-08-24 |
Xencor, Inc. |
结合cd3和cd38的异二聚体抗体
|
|
JP6696982B2
(ja)
|
2014-11-26 |
2020-05-20 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
|
|
TWI701258B
(zh)
|
2014-12-19 |
2020-08-11 |
美商再生元醫藥公司 |
流行性感冒病毒血球凝集素之人類抗體
|
|
EP3233912B1
(en)
|
2014-12-19 |
2021-05-19 |
Regenesance B.V. |
Antibodies that bind human c6 and uses thereof
|
|
AR103268A1
(es)
|
2014-12-23 |
2017-04-26 |
Bristol Myers Squibb Co |
Anticuerpos contra tigit
|
|
CN107438622A
(zh)
*
|
2015-03-19 |
2017-12-05 |
瑞泽恩制药公司 |
选择结合抗原的轻链可变区的非人动物
|
|
AU2016271111B2
(en)
|
2015-05-29 |
2022-04-28 |
Bristol-Myers Squibb Company |
Antibodies against OX40 and uses thereof
|
|
MX2017016502A
(es)
|
2015-06-29 |
2018-03-12 |
Univ Rockefeller |
Anticuerpos contra cd40 con actividad agonista mejorada.
|
|
JP6993958B2
(ja)
|
2015-07-06 |
2022-02-04 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
多重特異性抗原結合分子およびその使用
|
|
WO2017010874A1
(en)
|
2015-07-10 |
2017-01-19 |
Merus N.V. |
Human cd3 binding antibody
|
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
MY195059A
(en)
|
2015-09-23 |
2023-01-05 |
Regeneron Pharma |
Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
TWI824372B
(zh)
|
2015-10-12 |
2023-12-01 |
美商再生元醫藥公司 |
活化瘦素受體的抗原結合蛋白
|
|
JP7296728B2
(ja)
|
2015-10-23 |
2023-06-23 |
メルス ナムローゼ フェンノートシャップ |
癌の成長を抑制する結合分子
|
|
MX2018006072A
(es)
|
2015-11-19 |
2018-08-01 |
Squibb Bristol Myers Co |
Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
|
|
ES2954153T3
(es)
|
2015-12-22 |
2023-11-20 |
Regeneron Pharma |
Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
|
|
US20190037816A1
(en)
|
2016-01-13 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
Rodents having an engineered heavy chain diversity region
|
|
AU2017228470A1
(en)
|
2016-03-04 |
2018-08-30 |
Bristol-Myers Squibb Company |
Combination therapy with anti-CD73 antibodies
|
|
CN116063494A
(zh)
|
2016-03-04 |
2023-05-05 |
洛克菲勒大学 |
具有增强的激动剂活性的cd40的抗体
|
|
WO2017190079A1
(en)
|
2016-04-28 |
2017-11-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
|
US10968279B2
(en)
|
2016-05-09 |
2021-04-06 |
Bristol-Myers Squibb Company |
TL1A antibodies and uses thereof
|
|
TWI822521B
(zh)
|
2016-05-13 |
2023-11-11 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
|
SG10202102885UA
(en)
|
2016-05-20 |
2021-05-28 |
Regeneron Pharma |
Methods for breaking immunological tolerance using multiple guide rnas
|
|
CN109640644B
(zh)
|
2016-06-03 |
2021-10-26 |
瑞泽恩制药公司 |
表达外源末端脱氧核苷酸转移酶的非人动物
|
|
IL263481B2
(en)
|
2016-06-14 |
2024-06-01 |
Regeneron Pharma |
Anti-c5 antibodies and uses thereof
|
|
IL299221A
(en)
*
|
2016-06-21 |
2023-02-01 |
Teneobio Inc |
Cd3 binding antibodies
|
|
RU2019102008A
(ru)
|
2016-06-28 |
2020-07-28 |
Ксенкор, Инк. |
Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
|
|
US20190248893A1
(en)
|
2016-07-14 |
2019-08-15 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
|
HUE065861T2
(hu)
|
2016-08-26 |
2024-06-28 |
Sanofi Sa |
Szelektív könnyûlánc-párosítást elõsegítõ multispecifikus antitestek
|
|
WO2018044970A1
(en)
|
2016-08-31 |
2018-03-08 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
|
|
CR20220578A
(es)
*
|
2016-09-14 |
2023-01-17 |
Teneobio Inc |
Anticuerpos de unión a cd3
|
|
KR102531251B1
(ko)
|
2016-09-23 |
2023-05-15 |
리제너론 파아마슈티컬스, 인크. |
이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
|
|
KR102520731B1
(ko)
|
2016-09-23 |
2023-04-14 |
리제너론 파아마슈티컬스, 인크. |
항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도
|
|
CA3040189A1
(en)
|
2016-10-13 |
2018-04-19 |
Massachusetts Institute Of Technology |
Antibodies that bind zika virus envelope protein and uses thereof
|
|
EP3559035A1
(en)
|
2016-12-21 |
2019-10-30 |
TeneoBio, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
BR112019016336A2
(pt)
|
2017-02-10 |
2020-03-31 |
Regeneron Pharmaceuticals, Inc. |
Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
|
|
JP7136790B2
(ja)
|
2017-02-17 |
2022-09-13 |
ブリストル－マイヤーズ スクイブ カンパニー |
アルファ－シヌクレインに対する抗体およびその使用
|
|
EP3589650A1
(en)
|
2017-03-02 |
2020-01-08 |
Novartis AG |
Engineered heterodimeric proteins
|
|
JP7737220B2
(ja)
|
2017-03-31 |
2025-09-10 |
メルス ナムローゼ フェンノートシャップ |
ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
EP3625264B9
(en)
|
2017-05-17 |
2023-10-25 |
Merus N.V. |
Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
|
|
AU2018281280B2
(en)
|
2017-06-07 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for internalizing enzymes
|
|
JP7240335B2
(ja)
|
2017-06-20 |
2023-03-15 |
テネオワン， インコーポレイテッド |
抗ｂｃｍａ重鎖のみ抗体
|
|
CN110891971B
(zh)
|
2017-06-20 |
2024-01-12 |
特尼奥生物股份有限公司 |
仅有重链的抗bcma抗体
|
|
GB201710984D0
(en)
*
|
2017-07-07 |
2017-08-23 |
Kymab Ltd |
Cells, vertebrates, populations & methods
|
|
TWI865430B
(zh)
|
2017-07-24 |
2024-12-11 |
美商再生元醫藥公司 |
穩定化之抗體組合物及其製法
|
|
RS66708B9
(sr)
|
2017-08-09 |
2025-08-29 |
Merus Nv |
Antitela koja se vezuju za egfr i cmet
|
|
BR112020004977A2
(pt)
|
2017-09-29 |
2020-10-06 |
Regeneron Pharmaceuticals, Inc. |
moléculas de ligação de antígenos biespecíficas que ligam antígeno alvo de staphyocococcus e componente de complemento e usos dos mesmos
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
AU2018383751B2
(en)
|
2017-12-13 |
2025-05-08 |
Regeneron Pharmaceuticals, Inc. |
Anti-C5 antibody combinations and uses thereof
|
|
EA202091557A1
(ru)
|
2017-12-22 |
2020-11-18 |
Тенеобио, Инк. |
Антитела, содержащие только тяжелые цепи, которые связываются с cd22
|
|
JP7358361B2
(ja)
|
2018-01-12 |
2023-10-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｔｉｍ３に対する抗体およびその使用
|
|
SG11202006379UA
(en)
|
2018-01-26 |
2020-07-29 |
Regeneron Pharma |
Human antibodies to influenza hemagglutinin
|
|
JP7351845B2
(ja)
|
2018-03-23 |
2023-09-27 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
|
|
EP4534560A3
(en)
|
2018-03-24 |
2025-06-11 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
SMT202500283T1
(it)
|
2018-04-06 |
2025-09-12 |
Regeneron Pharma |
Un anticorpo agonista del recettore della leptina da utilizzare per aumentare la massa ossea in un soggetto affetto da disfunzione metabolica o ipoleptinemia
|
|
JP7328990B2
(ja)
|
2018-04-30 |
2023-08-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｈｅｒ２及び／またはａｐｌｐ２に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用
|
|
EP3793591A1
(en)
|
2018-05-17 |
2021-03-24 |
Regeneron Pharmaceuticals, Inc. |
Anti-cd63 antibodies, conjugates, and uses thereof
|
|
CN112513081A
(zh)
|
2018-06-14 |
2021-03-16 |
生物蛋白有限公司 |
多重特异性抗体构建体
|
|
IL318469A
(en)
|
2018-06-14 |
2025-03-01 |
Regeneron Pharma |
Non-human animals capable of reorganizing transgenic DH-DH, and their uses
|
|
CN119143875A
(zh)
|
2018-06-21 |
2024-12-17 |
瑞泽恩制药公司 |
双特异性抗psma x抗cd28抗体及其用途
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
MX2021002165A
(es)
|
2018-08-23 |
2021-07-16 |
Regeneron Pharma |
Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de éstos.
|
|
ES3009025T3
(en)
|
2018-08-31 |
2025-03-25 |
Regeneron Pharma |
Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
|
|
CA3115102A1
(en)
|
2018-10-23 |
2020-04-30 |
Regeneron Pharmaceuticals, Inc. |
Anti-npr1 antibodies and uses thereof
|
|
MX2021005708A
(es)
|
2018-11-16 |
2021-09-21 |
Bristol Myers Squibb Co |
Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
|
|
JP7463366B2
(ja)
|
2018-11-20 |
2024-04-08 |
タケダ ワクチン，インコーポレイテッド |
新規の抗ジカウイルス抗体及びその使用
|
|
CA3110377A1
(en)
|
2018-11-21 |
2020-05-28 |
Regeneron Pharmaceuticals, Inc. |
Anti-staphylococcus antibodies and uses thereof
|
|
KR20210104836A
(ko)
|
2018-12-19 |
2021-08-25 |
리제너론 파아마슈티컬스, 인크. |
이중 특이적 항-cd28 x 항-cd22 항체 및 그의 용도
|
|
WO2020132024A1
(en)
|
2018-12-19 |
2020-06-25 |
Regeneron Pharmaceuticals, Inc. |
Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
|
|
EP3897117A1
(en)
|
2018-12-21 |
2021-10-27 |
Compass Therapeutics LLC |
Transgenic mouse expressing common human light chain
|
|
CN118894938A
(zh)
|
2019-01-22 |
2024-11-05 |
百时美施贵宝公司 |
抗IL-7Rα亚基的抗体及其用途
|
|
JP2022519631A
(ja)
|
2019-02-12 |
2022-03-24 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
補体および標的抗原に結合する二重特異性抗体を使用するための組成物および方法
|
|
WO2020169022A1
(en)
|
2019-02-18 |
2020-08-27 |
Beijing Biocytogen Co., Ltd |
Genetically modified non-human animals with humanized immunoglobulin locus
|
|
BR112021016173A2
(pt)
|
2019-02-22 |
2021-11-03 |
Regeneron Pharma |
Roedor geneticamente modificado, métodos de produção de um roedor geneticamente modificado e de produção de um anticorpo anti-nav1.7, célula ou tecido isolado de roedor, linhagem celular imortalizada, embrião de roedor, construto de ácido nucleico de direcionamento, e, hibridoma
|
|
EP3941941A1
(en)
|
2019-03-22 |
2022-01-26 |
Regeneron Pharmaceuticals, Inc. |
Egfr x cd28 multispecific antibodies
|
|
CA3133654A1
(en)
|
2019-04-05 |
2020-10-08 |
Teneobio, Inc. |
Heavy chain antibodies binding to psma
|
|
PT3979790T
(pt)
|
2019-06-05 |
2026-05-05 |
Regeneron Pharma |
Roedores possuindo um reportrio limitado de cadeias leves lambda expressadas a partir do lcus kappa e suas utilizaes
|
|
CN113966343A
(zh)
|
2019-06-11 |
2022-01-21 |
瑞泽恩制药公司 |
结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法
|
|
CN114206927B
(zh)
|
2019-06-14 |
2025-03-21 |
特尼奥生物股份有限公司 |
与cd22和cd3结合的多特异性重链抗体
|
|
JP7743314B2
(ja)
|
2019-06-21 |
2025-09-24 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｍｕｃ１６およびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用
|
|
EP3986933A1
(en)
|
2019-06-21 |
2022-04-27 |
Regeneron Pharmaceuticals, Inc. |
Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
|
|
CN114585651A
(zh)
|
2019-08-08 |
2022-06-03 |
再生元制药公司 |
新型抗原结合分子形式
|
|
MX2022001942A
(es)
|
2019-08-15 |
2022-07-27 |
Regeneron Pharma |
Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas.
|
|
GB201912008D0
(en)
|
2019-08-21 |
2019-10-02 |
Cambridge Entpr Ltd |
Antibody
|
|
JP7611908B2
(ja)
|
2019-10-28 |
2025-01-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗血球凝集素抗体およびその使用方法
|
|
WO2021113297A1
(en)
|
2019-12-02 |
2021-06-10 |
Regeneron Pharmaceuticals, Inc. |
Peptide-mhc ii protein constructs and uses thereof
|
|
JP7693672B2
(ja)
|
2019-12-06 |
2025-06-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法
|
|
KR20210095781A
(ko)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
|
|
US11945872B2
(en)
|
2020-02-11 |
2024-04-02 |
Regeneron Pharmaceuticals, Inc. |
Anti-ACVR1 antibodies and uses thereof
|
|
KR20250007022A
(ko)
|
2020-04-29 |
2025-01-13 |
테네오원, 인코포레이티드 |
변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
|
|
MX2022014090A
(es)
|
2020-05-12 |
2023-02-27 |
Regeneron Pharma |
Anticuerpos antagonistas anti-glp1r y metodos de uso de los mismos.
|
|
EP4149632A1
(en)
|
2020-05-14 |
2023-03-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind msln and cd3
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
CN115667532A
(zh)
*
|
2020-06-02 |
2023-01-31 |
百奥赛图(北京)医药科技股份有限公司 |
具有共有轻链免疫球蛋白基因座的经遗传修饰的非人动物
|
|
US11919958B2
(en)
*
|
2020-08-19 |
2024-03-05 |
Xencor, Inc. |
Anti-CD28 compositions
|
|
US20220090060A1
(en)
|
2020-09-11 |
2022-03-24 |
Regeneron Pharmaceuticals, Inc. |
Identification and production of antigen-specific antibodies
|
|
JP7905328B2
(ja)
|
2020-09-18 |
2026-08-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｃｄ３８及び／又はｃｄ２８を結合する抗原結合分子及びその使用
|
|
US11866502B2
(en)
|
2020-10-22 |
2024-01-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-FGFR2 antibodies and methods of use thereof
|
|
CN118878693A
(zh)
|
2020-11-23 |
2024-11-01 |
康诺亚生物医药科技（成都）有限公司 |
一种双特异性抗体及其用途
|
|
WO2022130023A1
(en)
|
2020-12-14 |
2022-06-23 |
University Health Network |
Immunoglobulin light chain antibodies and uses thereof
|
|
EP4262373A1
(en)
|
2020-12-16 |
2023-10-25 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing humanized fc alpha receptors
|
|
US12325752B2
(en)
|
2020-12-18 |
2025-06-10 |
Regeneron Pharmaceuticals, Inc. |
Immunoglobulin proteins that bind to NPR1 agonists
|
|
MX2023007401A
(es)
|
2020-12-23 |
2023-07-06 |
Regeneron Pharma |
Acidos nucleicos que codifican anticuerpos modificados por anclaje y usos de los mismos.
|
|
CA3197426A1
(en)
|
2020-12-23 |
2022-06-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
|
|
CA3202891A1
(en)
|
2021-01-28 |
2022-08-04 |
Kara Olson |
Compositions and methods for treating cytokine release syndrome
|
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
|
CN116981357A
(zh)
|
2021-03-31 |
2023-10-31 |
瑞泽恩制药公司 |
包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
|
|
WO2023107957A1
(en)
|
2021-12-06 |
2023-06-15 |
Regeneron Pharmaceuticals, Inc. |
Antagonist anti-npr1 antibodies and methods of use thereof
|
|
IL314993A
(en)
|
2022-02-23 |
2024-10-01 |
Xencor Inc |
Anti-cd28 x anti-psma antibodies
|
|
TW202400228A
(zh)
|
2022-02-25 |
2024-01-01 |
美商再生元醫藥公司 |
減輕細胞激素釋放症候群的給藥方案
|
|
EP4496817A4
(en)
*
|
2022-03-22 |
2026-03-18 |
Univ Leland Stanford Junior |
Monoclonal antibodies designed to target the cardiac conduction system
|
|
WO2023196903A1
(en)
|
2022-04-06 |
2023-10-12 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
|
|
AU2023254191A1
(en)
|
2022-04-11 |
2024-10-17 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for universal tumor cell killing
|
|
CA3252182A1
(en)
|
2022-05-18 |
2023-11-23 |
Regeneron Pharmaceuticals, Inc. |
MULTISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND TO CD38 AND 4-1BB AND ASSOCIATED USES
|
|
WO2024015816A1
(en)
|
2022-07-12 |
2024-01-18 |
Regeneron Pharmaceuticals, Inc. |
Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
|
|
WO2024092133A1
(en)
|
2022-10-27 |
2024-05-02 |
Regeneron Pharmaceuticals, Inc. |
Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification
|
|
GB202217978D0
(en)
*
|
2022-11-30 |
2023-01-11 |
Petmedix Ltd |
Rodents expressing a common light chain
|
|
TW202615661A
(zh)
|
2023-01-18 |
2026-04-16 |
美商基利科學股份有限公司 |
人類免疫球蛋白二元輕鏈轉殖基因構築體及其用途
|
|
US20260217828A1
(en)
|
2023-01-31 |
2026-07-30 |
University Of Rochester |
Immune checkpoint blockade therapy for treating staphylococcus aureus infections
|
|
WO2024173248A1
(en)
|
2023-02-13 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
Treatment of muscle related disorders with anti-human cacng1 antibodies
|
|
AU2024223918A1
(en)
|
2023-02-17 |
2025-09-11 |
Regeneron Pharmaceuticals, Inc. |
Induced nk cells responsive to cd3/taa bispecific antibodies
|
|
CN121039163A
(zh)
|
2023-05-02 |
2025-11-28 |
瑞泽恩制药公司 |
抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途
|
|
EP4727973A1
(en)
|
2023-06-16 |
2026-04-22 |
Regeneron Pharmaceuticals, Inc. |
Cd40 x cd40 bispecific antigen-binding molecules and uses thereof
|
|
JP2026524012A
(ja)
|
2023-07-10 |
2026-07-16 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
二重特異性ｐｄ－ｌ１×４－１ｂｂ抗体およびそれらの使用方法
|
|
JP2026524011A
(ja)
|
2023-07-10 |
2026-07-16 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
二重特異性ｐｄ－ｌ１×ｃｄ２８抗体およびそれらの使用方法
|
|
IL325400A
(en)
|
2023-07-10 |
2026-02-01 |
Regeneron Pharma |
Anti-human CACNG1 antibody-drug conjugates and their uses
|
|
WO2025042428A1
(en)
|
2023-08-18 |
2025-02-27 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules and uses thereof
|
|
WO2025064761A1
(en)
|
2023-09-22 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Kras10-18 g12d off-target peptides and uses thereof
|
|
WO2025064738A1
(en)
|
2023-09-22 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Dntt 250-258 off-target peptides and uses thereof
|
|
CN118339300A
(zh)
*
|
2024-01-02 |
2024-07-12 |
江苏集萃药康生物科技股份有限公司 |
产生人源化抗体的动物模型及其构建方法
|
|
WO2025160340A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
US20250242056A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
US20250361320A1
(en)
|
2024-02-27 |
2025-11-27 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
US20250277048A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
WO2025199278A2
(en)
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Masked multispecific antigen-binding molecules with cleavable linkers
|
|
US20260000758A1
(en)
|
2024-06-28 |
2026-01-01 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof
|
|
WO2026006724A1
(en)
|
2024-06-28 |
2026-01-02 |
Regeneron Pharmaceuticals, Inc. |
Prame off-target peptides and uses thereof
|
|
WO2026006734A1
(en)
|
2024-06-28 |
2026-01-02 |
Regeneron Pharmaceuticals, Inc. |
Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development
|
|
US20260014252A1
(en)
|
2024-07-11 |
2026-01-15 |
Regeneron Pharmaceuticals, Inc. |
GPRC5D x CD28 Bispecific Antibodies and Methods of Use Thereof
|
|
US20260022395A1
(en)
|
2024-07-16 |
2026-01-22 |
Gilead Sciences, Inc. |
Human immunoglobulin common light chain transgene constructs and uses thereof
|
|
WO2026030428A2
(en)
|
2024-08-01 |
2026-02-05 |
Regeneron Pharmaceuticals, Inc. |
Prostate-specific antigen peptides and uses thereof
|
|
US20260123608A1
(en)
|
2024-08-06 |
2026-05-07 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
|
|
WO2026050255A2
(en)
|
2024-08-27 |
2026-03-05 |
Regeneron Pharmaceuticals, Inc. |
Anti-slc3a2-apis antigen-binding proteins and methods of use thereof
|
|
WO2026096576A1
(en)
|
2024-10-30 |
2026-05-07 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen-binding molecules that bind psma and 4-1bb and methods of use thereof
|
|
US20260146100A1
(en)
|
2024-10-30 |
2026-05-28 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen-binding molecules that bind cd22 and 4-1bb and methods of use thereof
|
|
WO2026096736A1
(en)
|
2024-10-31 |
2026-05-07 |
Regeneron Pharmaceuticals, Inc. |
Rodents expressing humanized polymeric immunoglobulin receptor
|
|
US20260144885A1
(en)
|
2024-11-22 |
2026-05-28 |
Bristol-Myers Squibb Company |
Anti-lrrc15 antibodies and uses thereof
|
|
US20260144884A1
(en)
|
2024-11-22 |
2026-05-28 |
Bristol-Myers Squibb Company |
Anti-lrrc15 antibody drug conjugates
|
|
WO2026117523A2
(en)
|
2024-11-26 |
2026-06-04 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with a combination of a cancer vaccine and a taaxcd28 bispecific antigen-binding molecule
|